Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-05 10:24 am Purchase | 2024-01-26 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 2,555,996 5.200% | 720,000![]() (+39.22%) | Filing History |
| 2024-02-02 09:59 am Sale | 2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | Soleus Capital Master Fund, L.P. | 0 0.000% | -50,000![]() (Position Closed) | Filing History |
| 2024-02-02 09:56 am Purchase | 2023-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL | Soleus Capital Master Fund, L.P. | 944,258 5.400% | 21,956![]() (+2.38%) | Filing History |
| 2024-02-02 09:54 am Purchase | 2023-12-31 | 13G | Organogenesis Holdings Inc. ORGO | Soleus Capital Master Fund, L.P. | 8,963,000 6.800% | 1,599,937![]() (+21.73%) | Filing History |
| 2024-02-02 09:53 am Sale | 2023-12-31 | 13G | Surmodics, Inc. SRDX | Soleus Capital Master Fund, L.P. | 771,700 5.400% | -3,611![]() (-0.47%) | Filing History |
| 2024-02-02 09:50 am Purchase | 2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | Soleus Capital Master Fund, L.P. | 987,096 8.800% | 987,096![]() (New Position) | Filing History |
| 2024-02-02 09:49 am Purchase | 2023-12-31 | 13G | Verastem, Inc. VSTM | Soleus Capital Master Fund, L.P. | 1,425,634 6.800% | 128,265![]() (+9.89%) | Filing History |
| 2024-02-02 09:44 am Sale | 2023-12-31 | 13G | IRadimed Corporation IRMD | Soleus Capital Master Fund, L.P. | 643,206 5.100% | -101,798![]() (-13.66%) | Filing History |
| 2024-02-02 09:42 am Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 703,868 5.000% | -187,000![]() (-20.99%) | Filing History |
| 2024-02-02 09:41 am Purchase | 2023-12-31 | 13G | Edap Tms S.a. EDAP | Soleus Capital Master Fund, L.P. | 7,226,341 19.600% | 2,091,911![]() (+40.74%) | Filing History |
| 2024-02-02 09:37 am Sale | 2023-12-31 | 13G | Delcath Systems, Inc. DCTH | Soleus Capital Master Fund, L.P. | 0 0.000% | -806,420![]() (Position Closed) | Filing History |
| 2024-02-02 09:34 am Sale | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 1,835,996 3.700% | -626,024![]() (-25.43%) | Filing History |
| 2024-02-02 09:29 am Sale | 2023-12-31 | 13G | AxoGen, Inc. AXGN | Soleus Capital Master Fund, L.P. | 2,595,815 6.000% | -945,483![]() (-26.70%) | Filing History |
| 2024-01-26 4:15 pm Purchase | 2024-01-23 | 13G | CalciMedica, Inc. CALC | Soleus Capital Master Fund, L.P. | 783,904 7.400% | 783,904![]() (New Position) | Filing History |
| 2023-11-28 4:52 pm Purchase | 2023-11-27 | 13D | Theratechnologies Inc. THTX | Soleus Capital Master Fund, L.P. | 5,188,876 10.500% | 5,188,876![]() (New Position) | Filing History |
| 2023-11-02 4:15 pm Purchase | 2023-11-01 | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund, L.P. | 890,868 6.400% | 890,868![]() (New Position) | Filing History |
| 2023-08-16 4:30 pm Purchase | 2023-08-15 | 13G | Delcath Systems, Inc. DCTH | Soleus Capital Master Fund, L.P. | 806,420 5.300% | 806,420![]() (New Position) | Filing History |
| 2023-08-11 4:31 pm Purchase | 2023-08-08 | 13G | AxoGen, Inc. AXGN | Soleus Capital Master Fund, L.P. | 3,541,298 8.200% | 3,541,298![]() (New Position) | Filing History |
| 2023-07-27 4:30 pm Purchase | 2023-07-26 | 13G | Verastem, Inc. VSTM | Soleus Capital Master Fund, L.P. | 1,297,369 5.100% | 1,297,369![]() (New Position) | Filing History |
| 2023-04-14 5:07 pm Purchase | 2023-04-13 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 2,462,020 5.000% | 2,462,020![]() (New Position) | Filing History |

